Nemolizumab (Galderma) is a subcutaneously injected interleukin-31 receptor alpha antagonist under investigation for the treatment of adult patients with prurigo nodularis.
Nemolizumab (Galderma) is a subcutaneously injected interleukin-31 receptor alpha antagonist under investigation for the treatment of adult patients with prurigo nodularis.